GLP1R and diabetes mellitus: In this regard, the glucagon-like peptide-1 (GLP-1) receptor agonist class may be an ideal candidate due to its primary mechanisms of action: reduction of postprandial glucose via increasing insulin secretion, decreasing glucagon secretion, and slowing gastric emptying [13], which leads to improved chronic glycemic control even when used in combination with other diabetes medications [14,15].